-transparent.png){kind=logo}
In this study we have examined, by means of isoelectric focusing (IEF) in native polyacrylamide gel and contact-print fluorescence zymography, whether human lung carcinomas and the lung parenchyma contain different pools of multiple charge forms of the cysteine proteinase cathepsin B. The isoelectric point (pI) patterns of cathepsin B from lung carcinoma and matched lung were similar, particularly with regard to 2 major intermediate acidic enzyme pI forms designated as I and II (pIapp of 5.10 and 4.93 in tumors, and 5.11 and 4.94 in lungs, respectively). The slightly acidic cathepsin B pI forms (pIapp 5.47-5.19) in squamous-cell lung carcinoma (SQCLC) were significantly more numerous than such enzyme pI forms in lungs. The numbers of the highly acidic cathepsin B pI forms (pIapp 4.82-4.33) were significantly higher in SQCLC and lung adenocarcinoma (ACL) than in matched lung. The activity distribution percentage in the set of highly acidic cathepsin B pI forms was significantly higher in SQCLC and ACL than in matched lung. We also observed that cathepsin B from SQCLC and matched lung was fully recoverable by IEF from inhibition by leupeptin. Using the cysteine-proteinase-specific inactivator E-64, we revealed by IEF that some cathepsin B isoforms (charge forms) from SQCLC were more resistant to inactivation by this compound than the corresponding enzyme isoforms from lungs. After IEF, the enzyme isoforms apparently lost their resistance to E-64. Our results indicate that the pool of multiple charge forms of cathepsin B in SQCLC and ACL is different from that in the lung, and also that there may be an increased level of loose complexes between cathepsin B and some proteins or polypeptides in SQCLC compared to the lung.
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
March 1992,
Biochimica et biophysica acta,
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
June 2014,
Proteomics. Clinical applications,
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
July 1994,
Cancer,
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
September 1990,
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society,
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
January 1981,
Ukrainskii biokhimicheskii zhurnal (1978),
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
January 1996,
Enzyme & protein,
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
January 1983,
Biomedica biochimica acta,
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
July 1997,
Clinical & experimental metastasis,
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
January 1990,
Neoplasma,
E Krepela, and
J Procházka, and
H Mynaríková, and
B Kárová, and
J Polák, and
J Cermák, and
H Roubková
December 1996,
Acta medica Okayama,
